Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
4 weeks Minimum interval between dose increases 2mg to 12mg Phase 2 dose range (Jastreboff 2023) ~12 weeks Time to reach 12mg on standard protocol 24.2% Weight loss at 12mg, 48 weeks (Phase 2) Investigational Drug Warning Retatrutide (LY3437943) is not FDA-approved as of April 2026
AOD 9604 activates beta-3 adrenergic receptors (AR) in adipose tissue, triggering lipolysis (i.e
Join the hundreds of successful patients in Hurst who trust Wellness Spot
Studies have indicated that Tirzepatide may reduce the risk of cardiovascular events, making it a comprehensive treatment option for those with type 2 diabetes
US$ 21.24
US$ 20.12
US$ 27.56
US$ 26.35
US$ 29.29
US$ 22.89
US$ 22.41
